FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2785464562> ?p ?o ?g. }

• W2785464562 endingPage "675" @default.
• W2785464562 startingPage "667" @default.
• W2785464562 abstract "Purpose To assess the clinical safety, pharmacokinetics, and tumor imaging characteristics of fluorine 18–(2S,4R)-4-fluoroglutamine (FGln), a glutamine analog radiologic imaging agent. Materials and Methods This study was approved by the institutional review board and conducted under a U.S. Food and Drug Administration–approved Investigational New Drug application in accordance with the Helsinki Declaration and the Health Insurance Portability and Accountability Act. All patients provided written informed consent. Between January 2013 and October 2016, 25 adult patients with cancer received an intravenous bolus of FGln tracer (mean, 244 MBq ± 118, <100 μg) followed by positron emission tomography (PET) and blood radioassays. Patient data were summarized with descriptive statistics. FGln biodistribution and plasma amino acid levels in nonfasting patients (n = 13) were compared with those from patients who fasted at least 8 hours before injection (n = 12) by using nonparametric one-way analysis of variance with Bonferroni correction. Tumor FGln avidity versus fluorodeoxyglucose (FDG) avidity in patients with paired PET scans (n = 15) was evaluated with the Fisher exact test. P < .05 was considered indicative of a statistically significant difference. Results FGln PET depicted tumors of different cancer types (breast, pancreas, renal, neuroendocrine, lung, colon, lymphoma, bile duct, or glioma) in 17 of the 25 patients, predominantly clinically aggressive tumors with genetic mutations implicated in abnormal glutamine metabolism. Acute fasting had no significant effect on FGln biodistribution and plasma amino acid levels. FGln-avid tumors were uniformly FDG-avid but not vice versa (P = .07). Patients experienced no adverse effects. Conclusion Preliminary human FGln PET trial results provide clinical validation of abnormal glutamine metabolism as a potential tumor biomarker for targeted radiotracer imaging in several different cancer types. © RSNA, 2018 Online supplemental material is available for this article. Clinical trial registration no. NCT01697930" @default.
• W2785464562 created "2018-02-23" @default.
• W2785464562 creator A5016770897 @default.
• W2785464562 creator A5018829094 @default.
• W2785464562 creator A5020324479 @default.
• W2785464562 creator A5021734597 @default.
• W2785464562 creator A5024109107 @default.
• W2785464562 creator A5026066701 @default.
• W2785464562 creator A5029385885 @default.
• W2785464562 creator A5031628518 @default.
• W2785464562 creator A5033270808 @default.
• W2785464562 creator A5040275059 @default.
• W2785464562 creator A5042102358 @default.
• W2785464562 creator A5055131918 @default.
• W2785464562 creator A5056859109 @default.
• W2785464562 creator A5065435809 @default.
• W2785464562 creator A5068928963 @default.
• W2785464562 creator A5069721801 @default.
• W2785464562 creator A5069929201 @default.
• W2785464562 creator A5080877411 @default.
• W2785464562 creator A5087914233 @default.
• W2785464562 date "2018-05-01" @default.
• W2785464562 modified "2023-09-30" @default.
• W2785464562 title "In Vivo PET Assay of Tumor Glutamine Flux and Metabolism: In-Human Trial of ¹⁸F-(2<i>S</i>,4<i>R</i>)-4-Fluoroglutamine" @default.
• W2785464562 cites W13950245 @default.
• W2785464562 cites W1898138780 @default.
• W2785464562 cites W1937512791 @default.
• W2785464562 cites W1964001245 @default.
• W2785464562 cites W1996365670 @default.
• W2785464562 cites W2005616300 @default.
• W2785464562 cites W2038652783 @default.
• W2785464562 cites W2043586467 @default.
• W2785464562 cites W2055255976 @default.
• W2785464562 cites W2056843519 @default.
• W2785464562 cites W2073824759 @default.
• W2785464562 cites W2074873270 @default.
• W2785464562 cites W2076284407 @default.
• W2785464562 cites W2087814592 @default.
• W2785464562 cites W2092152920 @default.
• W2785464562 cites W2093818073 @default.
• W2785464562 cites W2097259163 @default.
• W2785464562 cites W2097483643 @default.
• W2785464562 cites W2102186262 @default.
• W2785464562 cites W2110508238 @default.
• W2785464562 cites W2115682896 @default.
• W2785464562 cites W2131505590 @default.
• W2785464562 cites W2132117833 @default.
• W2785464562 cites W2142974837 @default.
• W2785464562 cites W2143973673 @default.
• W2785464562 cites W2149343603 @default.
• W2785464562 cites W2155263737 @default.
• W2785464562 cites W2160159824 @default.
• W2785464562 cites W2234115940 @default.
• W2785464562 cites W223909586 @default.
• W2785464562 cites W2259949170 @default.
• W2785464562 cites W2335012284 @default.
• W2785464562 cites W2497583477 @default.
• W2785464562 cites W2561074847 @default.
• W2785464562 doi "https://doi.org/10.1148/radiol.2017162610" @default.
• W2785464562 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5929369" @default.
• W2785464562 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/29388903" @default.
• W2785464562 hasPublicationYear "2018" @default.
• W2785464562 type Work @default.
• W2785464562 sameAs 2785464562 @default.
• W2785464562 citedByCount "75" @default.
• W2785464562 countsByYear W27854645622018 @default.
• W2785464562 countsByYear W27854645622019 @default.
• W2785464562 countsByYear W27854645622020 @default.
• W2785464562 countsByYear W27854645622021 @default.
• W2785464562 countsByYear W27854645622022 @default.
• W2785464562 countsByYear W27854645622023 @default.
• W2785464562 crossrefType "journal-article" @default.
• W2785464562 hasAuthorship W2785464562A5016770897 @default.
• W2785464562 hasAuthorship W2785464562A5018829094 @default.
• W2785464562 hasAuthorship W2785464562A5020324479 @default.
• W2785464562 hasAuthorship W2785464562A5021734597 @default.
• W2785464562 hasAuthorship W2785464562A5024109107 @default.
• W2785464562 hasAuthorship W2785464562A5026066701 @default.
• W2785464562 hasAuthorship W2785464562A5029385885 @default.
• W2785464562 hasAuthorship W2785464562A5031628518 @default.
• W2785464562 hasAuthorship W2785464562A5033270808 @default.
• W2785464562 hasAuthorship W2785464562A5040275059 @default.
• W2785464562 hasAuthorship W2785464562A5042102358 @default.
• W2785464562 hasAuthorship W2785464562A5055131918 @default.
• W2785464562 hasAuthorship W2785464562A5056859109 @default.
• W2785464562 hasAuthorship W2785464562A5065435809 @default.
• W2785464562 hasAuthorship W2785464562A5068928963 @default.
• W2785464562 hasAuthorship W2785464562A5069721801 @default.
• W2785464562 hasAuthorship W2785464562A5069929201 @default.
• W2785464562 hasAuthorship W2785464562A5080877411 @default.
• W2785464562 hasAuthorship W2785464562A5087914233 @default.
• W2785464562 hasBestOaLocation W27854645621 @default.
• W2785464562 hasConcept C112705442 @default.
• W2785464562 hasConcept C126322002 @default.
• W2785464562 hasConcept C150903083 @default.
• W2785464562 hasConcept C185592680 @default.
• W2785464562 hasConcept C197934379 @default.
• W2785464562 hasConcept C207001950 @default.

• next